Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Good competition.
Sunday, May 10, 2020
YOUR RIGHT TO KNOW
Home Front Page
12:00 AM, May 10, 2020 / LAST MODIFIED: 02:30 AM, May 10, 2020
Remdesivir: Eskayef submits samples to DGDA
Staff Correspondent
Leading pharmaceuticals company Eskayef yesterday submitted samples of remdesivir, the drug used for treating Covid-19 patients, to the deputy chief of the Directorate General of Drug Administration (DGDA).
The reference number of the generic drug with brand name Remivir is SKF/DTL-SAMPLE/2020/14, said a press release from Eskayef, adding that it received DGDA approval on pricing of the drug on April 7.
Once the approval comes from the testing laboratory, the drug will be supplied to the markets in a few days, said the release.
DGDA RELEASE
Meanwhile, the DGDA yesterday sent a press release to the media, clarifying the issue over the production of the drug.
In the press release, signed by DGDA Director Ruhul Amin, the drug administration said it would issue marketing authoritisation certificate to Eskayef for supplying the drug to the market if the result of the samples sent to the laboratory for testing was satisfactory.
PRESS NOTE FROM BEXIMCO
Beximco Pharmaceuticals Limited also issued a press note to the media regarding the production of remdesivir.
In the note, it claimed it is the first company to have produced the generic drug in the country.
On Saturday, several newspapers reported that the drug was first produced in the country by Eskayef.
In the note, Beximco said the news was "confusing" and "factually incorrect".
On May 7, Beximco submitted samples of the drug to the DGDA for approval.
The anti-viral drug remdesivir has been proved to fight against coronavirus infection. It was invented by US-based biopharmaceutical company Gilead Sciences, Inc
For those who are unaware, Eskayef Bangladesh is an independent subsidiary of Smith, Kline and French which is a global pharma company. In 2000, SKF was acquired by Glaxo Wellcome (now GlaxoSmithKline).